A detailed history of Russell Investments Group, Ltd. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 173,788 shares of CPRX stock, worth $3.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
173,788
Previous 215,537 19.37%
Holding current value
$3.73 Million
Previous $3.34 Million 3.48%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.19 - $21.35 $634,167 - $891,341
-41,749 Reduced 19.37%
173,788 $3.45 Million
Q2 2024

Aug 08, 2024

SELL
$14.68 - $16.92 $325,998 - $375,742
-22,207 Reduced 9.34%
215,537 $3.34 Million
Q1 2024

May 08, 2024

BUY
$13.18 - $17.11 $604,474 - $784,715
45,863 Added 23.9%
237,744 $3.79 Million
Q4 2023

Feb 05, 2024

BUY
$11.78 - $17.29 $117,953 - $173,124
10,013 Added 5.51%
191,881 $3.23 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $169,762 - $218,120
-14,522 Reduced 7.39%
181,868 $2.13 Million
Q2 2023

Aug 10, 2023

SELL
$11.5 - $18.08 $1.91 Million - $3 Million
-166,127 Reduced 45.83%
196,390 $2.64 Million
Q1 2023

May 09, 2023

BUY
$14.34 - $21.05 $1.24 Million - $1.82 Million
86,231 Added 31.21%
362,517 $6.01 Million
Q4 2022

Feb 08, 2023

SELL
$12.25 - $19.5 $236,841 - $377,013
-19,334 Reduced 6.54%
276,286 $5.14 Million
Q3 2022

Nov 04, 2022

SELL
$7.06 - $15.52 $1.01 Million - $2.22 Million
-143,061 Reduced 32.61%
295,620 $3.79 Million
Q2 2022

Jul 29, 2022

BUY
$6.23 - $8.57 $218,461 - $300,515
35,066 Added 8.69%
438,681 $3.07 Million
Q1 2022

May 05, 2022

SELL
$5.31 - $8.31 $343,063 - $536,884
-64,607 Reduced 13.8%
403,615 $3.34 Million
Q4 2021

Jan 21, 2022

BUY
$5.21 - $7.45 $99,438 - $142,190
19,086 Added 4.25%
468,222 $3.17 Million
Q3 2021

Nov 08, 2021

SELL
$4.85 - $6.04 $169,764 - $211,418
-35,003 Reduced 7.23%
449,136 $2.38 Million
Q2 2021

Aug 04, 2021

SELL
$4.29 - $6.05 $755,194 - $1.07 Million
-176,036 Reduced 26.67%
484,139 $2.78 Million
Q1 2021

May 10, 2021

BUY
$3.45 - $4.69 $739,869 - $1.01 Million
214,455 Added 48.11%
660,175 $3.04 Million
Q4 2020

Feb 08, 2021

BUY
$2.97 - $3.83 $113,088 - $145,834
38,077 Added 9.34%
445,720 $1.49 Million
Q3 2020

Nov 09, 2020

BUY
$2.97 - $5.08 $280,920 - $480,496
94,586 Added 30.21%
407,643 $1.21 Million
Q2 2020

Aug 05, 2020

SELL
$3.48 - $5.05 $24,109 - $34,986
-6,928 Reduced 2.17%
313,057 $1.44 Million
Q1 2020

May 06, 2020

BUY
$2.61 - $5.21 $209,658 - $418,514
80,329 Added 33.52%
319,985 $1.23 Million
Q4 2019

Jan 29, 2020

BUY
$3.67 - $5.7 $879,537 - $1.37 Million
239,656 New
239,656 $896,000
Q4 2018

Feb 11, 2019

SELL
$1.92 - $3.62 $6,266 - $11,815
-3,264 Closed
0 $0
Q3 2018

Oct 26, 2018

SELL
$2.81 - $3.78 $27,321 - $36,752
-9,723 Reduced 74.87%
3,264 $12,000
Q2 2018

Aug 08, 2018

SELL
$2.26 - $3.84 $8,832 - $15,006
-3,908 Reduced 23.13%
12,987 $41,000
Q4 2017

Feb 06, 2018

SELL
$2.51 - $4.4 $2,010 - $3,524
-801 Reduced 4.53%
16,895 $68,000
Q3 2017

Nov 07, 2017

BUY
$2.4 - $2.94 $42,470 - $52,026
17,696
17,696 $44,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.21B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.